RAS与BRAF野生型转移性结直肠癌老年患者接受初始帕尼单抗联合FOLFOX或5-FU/LV治疗时对分子超选择的阴性预测价值
该研究对PANDA试验中老年RAS/BRAF野生型转移性结直肠癌患者的存档样本行全面基因组分析,检测HER2、MET、NTRK/ROS1/ALK/RET、PIK3CA外显子20、PTEN、AKT1、MAP2K1等改变。147例中41例(27.9%)检出至少一种改变,定义为基因组改变(GA)组,无改变者为超选择(HS)组。GA组较HS组无进展生存期、总生存期和客观缓解率均更差。
要点
- 147例中41例(27.9%)检出至少一种耐药相关基因组改变,归为GA组。
- GA组较HS组中位无进展生存期7.6个月对12.8个月更差(HR=2.08)。
- GA组较HS组客观缓解率51%对71%更低(OR=0.43)。
核心结论
- 分子超选择与全面基因组分析在适合初始EGFR抑制治疗的老年RAS/BRAF野生型、pMMR/MSS转移性结直肠癌患者中可能具有潜在应用价值。
研究设计与样本
- 对PANDA试验入组老年患者的存档样本行全面基因组分析,检测HER2扩增/突变、MET扩增、NTRK/ROS1/ALK/RET重排、PIK3CA外显子20突变、PTEN改变、AKT1突变、MAP2K1突变。
- 有至少一种改变者定义为基因组改变(GA)组,无改变者定义为超选择(HS)组,共分析147例患者。
- 将生存与肿瘤缓解结局与超选择状态单独或联合原发肿瘤部位或治疗臂进行相关性分析。
主要发现
- 147例中41例(27.9%)检出基因组改变。
- GA组较HS组中位无进展生存期7.6个月对12.8个月更差(HR=2.08,95%CI 1.43-3.03,p<0.001)。
- GA组较HS组中位总生存期20.0个月对29.5个月更差(HR=1.82,95%CI 1.23-2.69,p=0.002)。
- GA组较HS组客观缓解率51%对71%更低(OR=0.43,95%CI 0.21-0.91,p=0.02)。
- 多变量模型中,超选择对无进展生存期和总生存期的影响得到确认;GA组中5-FU/LV/帕尼单抗客观缓解率较低(40%对62%),而HS组无此差异(70%对72%)。
关键数值与推荐
- 无论原发肿瘤部位,GA均与更差的生存和缓解相关;在HS亚组中,右半与左半肿瘤结局相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Upfront anti-EGFR therapy represents the standard of care for patients with left-sided, MSS/pMMR, RAS and BRAF wild-type mCRC. Molecular 'hyperselection' may optimize EGFR inhibition by detecting additional resistance alterations. MATERIALS AND METHODS: We used comprehensive genomic profiling on archival samples of elderly patients enrolled in the PANDA trial to detect: HER2 amplification/mutations; MET amplification; NTRK/ROS1/ALK/RET rearrangements; PIK3CA exon 20 mutations; PTEN alterations; AKT1 mutations; MAP2K1 mutations. We defined 'Gene Altered' (GA) patients whose tumour harboured at least one alteration, and 'Hyperselected' (HS) those without. Survival and tumour response outcomes were correlated to hyperselection status alone or combined with primary tumour sidedness or treatment arm. RESULTS: Genomic alterations were detected in 41/147 patients (27.9%). PFS, OS and ORR were inferior in GA versus HS (median PFS: 7.6 versus 12.8 months, HR = 2.08, 95% CI: 1.43-3.03, p < 0.001; median OS: 20.0 versus 29.5 months, HR = 1.82, 95% CI:1.23-2.69, p = 0.002; ORR: 51% versus 71%; OR = 0.43, 95% CI: 0.21-0.91, p = 0.02). In the multivariable models, the impact of hyperselection on PFS and OS was confirmed. Lower ORR was observed with 5-FU/LV/panitumumab in GA (40% versus 62%), but not in HS (70% versus 72%). GA was associated with worse survival and response regardless of primary tumour sidedness, whereas in the HS subgroup, right-and left sided tumours had similar outcomes. CONCLUSIONS: Molecular hyperselection and comprehensive genomic profiling have a potential usefulness in elderly patients with RAS/BRAF wild-type, pMMR/MSS mCRC, eligible for upfront EGFR inhibition.
引用
- Pietrantonio F, Bergamo F, Rossini D, et al. Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV. Eur J Cancer. 2023. PMID: 37924647. doi:10.1016/j.ejca.2023.113396
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。